These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
    Author: Yoshida T, Nakamura S, Ohtake S, Ito K, Kobayashi K, Kanno M, Hirai J, Tachimori K, Matsuda T.
    Journal: Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717.
    Abstract:
    Effect of high dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) was studied clinically and pharmacologically in non-Hodgkin's lymphoma and acute leukemia. The schedule of drug administration consisted of daily i.v. infusion for 5 consecutive days. The daily close was initiated with 500 mg/m2 which was escalated up to 1300 mg/m2. Eruption was found to be dose-limiting toxicity and there was no myelosuppression. The plasma concentration curve of BH-AC showed a biphasic curve. The half-lives of the initial phase (t1/2 alpha) and the second phase (t1/2 beta) by the administration (1 hr iv infusion) of 700 mg/m2 were 1.08 and 3.65 h respectively. The plasma 1-beta-D-arabinofuranosylcytosine was detected for 12-24 hr after infusion (Cmax: 0.26 microgram/ml).
    [Abstract] [Full Text] [Related] [New Search]